 |
| Natural Killer Cells Market |
The global Natural Killer Cells Market is estimated to be valued at US$ 132.76 Mn in 2023 and is expected to exhibit a CAGR of 44.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Natural Killer (NK) Cells are a type of cytotoxic lymphocytes that play a major
role in the rejection of tumor cells and cells infected by viruses. They can
directly kill infected cells without prior activation. NK cells are being
explored for adoptive cell therapy for cancer treatment.
Market key trends:
One of the major trends in the Natural Killer Cells market is the increasing
focus on gene-edited NK cells. Gene editing techniques like CRISPR allow
scientists to modify the genes of NK cells to enhance its cancer killing
potential. Editing genes involved in the activation, proliferation and
cytotoxicity pathways helps improve the persistence and anti-tumor activity of
NK cells. This gives gene-edited NK cells an advantage over normal NK cells and
is expected to boost their adoption in adoptive cellular therapies for cancer
treatment.
Segment Analysis
The global Natural Killer (NK) cells market is segmented into thermal
immunotherapy, immunotherapy, and adoptive cell transfer based on therapy.
Among these, the adoptive cell transfer segment dominated the market in 2022
due to supportive research & funding for novel NK cell therapeutics.
Adoptive cell transfer therapy utilizes ex vivo expanded autologous or
allogenic NK cells to boost the body's immune response against cancer cells.
This immunotherpay helps eliminate tumor cells.
Key Takeaways
The global Natural
Killer Cells Market Growth is expected to witness high growth,
exhibiting a CAGR of 44.% over the
forecast period, due to increasing incidence of cancer globally. According to
WHO, cancer burden has risen to 19.3 million new cases and 10 million cancer
deaths in 2020.
Regional analysis
North America dominated the global market in 2022 and is expected to maintain
its lead over the forecast period. This is attributed to advancements in
genetic engineering and rising cancer prevalence in the US. The Asia Pacific
region is anticipated to be the fastest-growing market due to rising healthcare
investments and growing cancer research & immunotherapy development programs
in major economies like China and India.
Key players
Key players operating in the natural killer cells market are GC Cell (GC
Biopharma corp.), ImmunityBio, Inc., Nkarta, Inc., Takeda Pharmaceutical
Company Limited, Sanofi S. A., Innate Pharma SA. These players are focused on
research and development of various NK cell therapeutics for cancer treatment
through collaborative programs and clinical trials. For instance, in June 2022,
GC Pharma received approval from Ministry of Food and Drug Safety to initiate
Phase 1/2 clinical trial of GC027, an allogenic Natural Killer cell therapy
candidate, in patients with acute myeloid leukemia.
Comments
Post a Comment